Metastatic Breast Cancer Clinical Trials in Atlanta, Georgia
10 recruitingAtlanta, Georgia
Showing 1–10 of 10 trials
Recruiting
Phase 2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled139 locationsNCT06157892
Recruiting
Phase 3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+1 more
Olema Pharmaceuticals, Inc.510 enrolled233 locationsNCT06016738
Recruiting
Phase 1Phase 2
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Metastatic Breast CancerHER2-negative Breast CancerAdvanced Breast Cancer+1 more
RayzeBio, Inc.124 enrolled31 locationsNCT06590857
Recruiting
Phase 1Phase 2
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Metastatic Breast CancerLocally Advanced Breast CancerUnresectable Breast Carcinoma
BioNTech SE380 enrolled20 locationsNCT06827236
Recruiting
Phase 3
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Metastatic Breast Cancer
Sermonix Pharmaceuticals Inc.500 enrolled222 locationsNCT05696626
Recruiting
Phase 2
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
Metastatic Breast Cancer
Kathy Miller168 enrolled6 locationsNCT05846789
Recruiting
Phase 3
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Breast CancerBreast Cancer MetastaticMetastatic Breast Cancer+2 more
BriaCell Therapeutics Corporation404 enrolled77 locationsNCT06072612
Recruiting
Phase 2
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer
Reshma L. Mahtani, D.O.75 enrolled3 locationsNCT06263543
Recruiting
Phase 2
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Metastatic Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerRecurrent Breast Cancer
Puma Biotechnology, Inc.150 enrolled53 locationsNCT06369285
Recruiting
Phase 3
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Metastatic Breast Cancer
American Society of Clinical Oncology500 enrolled65 locationsNCT06377852